Related Experiment Videos
Botulinum toxin type A therapy for cervical dystonia
J Costa1, C Espírito-Santo, A Borges
1Instituto de Farmacologia e Terapêutica Geral, Faculdade de Medicina Lisboa, Av. Prof. Egas Moniz, Lisboa, Portugal, 1649-028. movementdisord@mail.telepac.pt
The Cochrane Database of Systematic Reviews
|January 28, 2005
Summary
Botulinum toxin Type A (BtA) effectively treats cervical dystonia, improving symptoms and reducing pain. This safe treatment offers significant benefits for patients, with continued efficacy in subsequent cycles.
Area of Science:
- Neurology
- Pharmacology
- Clinical Trials
Background:
- Cervical dystonia involves involuntary head posturing, neck pain, disability, and social withdrawal.
- Botulinum toxin Type A (BtA) is a primary therapy, but its precise efficacy and effect size require clarification.
Purpose of the Study:
- To evaluate the effectiveness and safety of Botulinum toxin Type A (BtA) for treating cervical dystonia.
Main Methods:
- Systematic review and meta-analysis of randomized controlled trials comparing BtA with placebo.
- Searched multiple databases (Cochrane, MEDLINE, EMBASE) and contacted manufacturers.
- Assessed trial quality, extracted data, and analyzed adverse events.
Main Results:
- Thirteen high-quality studies (Botox and Dysport) showed significant improvements in objective and subjective rating scales.
- BtA treatment led to statistically and clinically significant pain relief.
- Adverse events like neck weakness and dysphagia were more frequent but associated with BtA's mechanism; a dose-response relationship was observed.
Conclusions:
- A single Botulinum toxin Type A (BtA) injection cycle is effective and safe for cervical dystonia.
- Evidence suggests continued efficacy in subsequent treatment cycles for most patients.